Hot Stock to Watch: Gilead Sciences Inc. (GILD)

The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. During the trading on 04/19/2017, Company's stock ranged from $35.05 to $34.12. The company's institutional ownership is monitored at 78 percent.

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need.

A 52-week high/low is the highest and lowest price that a stock has traded at during the previous year.

The (Simple Month Average) SMA20 is at -1.03 percent, its SMA50 Value is -2.57% and SMA200 value is reported as -10.37 Percent. Lombard Odier Transatlantic Limited Partnership increased its stake in Gilead Sciences by 55.6% in the third quarter. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company's stock valued at $102,000 after buying an additional 774 shares during the period. Carlton Hofferkamp & Jenks Wealth Management LLC boosted its stake in shares of Gilead Sciences by 0.3% in the third quarter. The company now has a consensus rating of "Buy" and an average target price of $83.86.

If we look at the Volatility of the company, Week Volatility is 1.13%, whereas Month Volatility is at 1.15%. Girard Securities Inc.'s holdings in Gilead Sciences were worth $426,000 at the end of the most recent quarter. (NASDAQ:GILD) opened at 66.06 on Wednesday. Gilead Sciences has a 52-week low of $65.38 and a 52-week high of $103.10. The company has a market cap of $88.05 billion, a price-to-earnings ratio of 6.18 and a beta of 1.11. The company's 50 day moving average is $67.93 and its 200-day moving average is $71.87. Comparatively, Gilead Sciences Inc. posted earnings of $3.04 per share in the same quarter a year ago. Looking ahead to earnings forecasts, for the running fiscal period, Wall Street analysts have anticipated that the company will report 0.16 earnings per share. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The firm earned $7.30 billion during the quarter, compared to analysts' expectations of $7.16 billion. The fund owned 5,274,948 shares of the biopharmaceutical company's stock after buying an additional 3,327,900 shares during the period. The company reported revenue of $7.92 Billion in the same period a year ago.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Investors of record on Thursday, March 16th were paid a $0.52 dividend. This is an increase from Gilead Sciences's previous quarterly dividend of $0.47. This represents a $2.08 dividend on an annualized basis and a dividend yield of 3.13%. The firm has "Underweight" rating by Barclays Capital given on Tuesday, March 29. Gilead Sciences's payout ratio is now 17.44%.

COPYRIGHT VIOLATION WARNING: This story was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this story on another site, it was illegally stolen and reposted in violation of USA & worldwide trademark and copyright laws. The original version of this story can be read at

GILD has been the topic of a number of recent analyst reports. Cowen and Company now has a $100.00 price target on the biopharmaceutical company's stock. Royal Bank of Canada reiterated a "buy" rating and issued a $90.00 price objective on shares of Gilead Sciences in a research report on Tuesday, January 3rd. (NASDAQ:GILD) earned "Neutral" rating by Bank of America on Monday, January 18. Ratings and estimates change daily and thus the numbers may differ slightly if a new report has been issued within the last 24-hours. Recently, investment analysts covering the stock have updated the mean rating to 2.4. Technical analysis can help recognize key technical price levels in the stock. Earnings per share serves as an indicator of a company's profitability. The ATR (Average True Range) value is 0.82. The stock plunged -7.43 percent over the past quarter, while declined -7.91 percent over the past six months. (LEN) stake by 199.93% reported in 2016Q4 SEC filing. The shares were sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at $214,973,917.42. The disclosure for this sale can be found here. On Wednesday, November 9 Alton Gregg H sold $790,000 worth of Gilead Sciences, Inc.

Latest News